Bisoprolol etkileşimleri

beta bloker sınıfından Bisoprolol (Zebeta) için dizinlediğimiz FDA etiketlerinde ve bilgi sayfalarında 317 belgelenmiş etkileşim var: 12 majör, 253 orta, 50 minör ve bir etiketin anlamlı etkileşim olmadığını bildirdiği 2 çift. Aşağıdaki her kayıt, dayandığı cümleyi alıntılar. Bu ilaç sayfası bir başlangıç noktasıdır; sizin durumunuz için verilmiş bir hüküm değildir.

Bisoprolol nasıl görünür

27 sürümün tümü
Bisoprolol 5 mg tablet: pembe, yuvarlak, 6 mm, çentikli, üzerinde 111 baskısı var.
111
5 mg · pembe · yuvarlak · 6 mm · çentikli
Zydus Lifesciences
Bisoprolol 10 mg tablet: beyaz, yuvarlak, 7 mm, üzerinde 112 baskısı var.
112
10 mg · beyaz · yuvarlak · 7 mm
Zydus Lifesciences
Bisoprolol 5 mg tablet: beyaz, yuvarlak, 7 mm, çentikli, bir yüzünde B, diğer yüzünde 3 baskısı var.
B / 3
5 mg · beyaz · yuvarlak · 7 mm · çentikli
Alembic
Bisoprolol 10 mg tablet: beyaz, yuvarlak, 7 mm, üzerinde B4 baskısı var.
B4
10 mg · beyaz · yuvarlak · 7 mm
Alembic

Çizimler, FDA etiketlerindeki ürün bilgilerinden oluşturulmuştur: renk, şekil, boyut ve baskı. 18 firmaya ait 27 belgelenmiş sürüm.

Etikete göre etkileşimler

Majör etkileşimler (12)

  • Eptifibatidantitrombosit ilaçMajör

    …of active abnormal bleeding within the previous 30 days Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) not adequately controlled on antihypertensive therapy Major surgery within the preceding 6 weeks History of stroke within 30 days or any history of hemorrhagic stroke Current or planned administration of another… (Eptifibatid etiketi, Kontrendikasyonlar)

  • FlekainidantiaritmikMajör

    Concomitant negative chronotropic therapy such as digoxin or beta-blockers may lower the risk of this complication. (Flekainid etiketi, Kutulu uyarı)

  • KlozapinantipsikotikMajör

    Use CLOZARIL cautiously in patients with cardiovascular or cerebrovascular disease or conditions predisposing to hypotension (e.g., dehydration, use of antihypertensive medications) [see Dosage and Administration ( 2.2 , 2.6 ), Warnings and Precautions ( 5.2 )]. (Klozapin etiketi, Kutulu uyarı)

  • MetirozinMajör

    In addition, life-threatening arrhythmias may occur during anesthesia and surgery, and may require treatment with a beta-blocker or lidocaine. (Metirozin etiketi, Uyarılar)

  • Metolazontiyazid diüretikMajör

    Other Antihypertensive Drugs When metolazone tablets, USP, are used with other antihypertensive drugs, particular care must be taken to avoid excessive reduction of blood pressure, especially during initial therapy. (Metolazon etiketi, Uyarılar)

  • MinoksidilvazodilatörMajör

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (Minoksidil etiketi, Kutulu uyarı)

  • Nebivololbeta blokerMajör

    Hypotensive Agents Do not use BYSTOLIC with other β-blockers. (Nebivolol etiketi, İlaç etkileşimleri)

  • ProtaminMajör

    Risk factors include high dose or overdose, rapid administration (see WARNINGS and DOSAGE AND ADMINISTRATION ), repeated doses, previous administration of protamine, and current or previous use of protamine-containing drugs (NPH insulin, protamine zinc insulin, and certain beta-blockers). (Protamin etiketi, Kutulu uyarı)

  • RepaglinidmeglitinidMajör

    Examples: beta-blockers, clonidine, guanethidine, and reserpine Clopidogrel : Avoid concomitant use; if used concomitantly initiate at 0.5 mg before each meal and limit total daily dose to 4 mg ( 7 ) (Repaglinid etiketi, İlaç etkileşimleri)

  • Rivastigminkolinesteraz inhibitörüMajör

    Concomitant use with metoclopramide, beta-blockers, or cholinomimetic and anticholinergic drugs is not recommended ( 7.1 , 7.2 , 7.3 ) (Rivastigmin etiketi, İlaç etkileşimleri)

  • TadalafilPDE5 inhibitörüMajör

    …coadministration of an alpha-blocker and CIALIS for the treatment of BPH has not been adequately studied, and due to the potential vasodilatory effects of combined use resulting in blood pressure lowering, the combination of CIALIS and alpha-blockers is not recommended for the treatment of BPH. [see Dosage and Administration ( 2.7 ), Drug Interactions ( 7.1 ),… (Tadalafil etiketi, Uyarılar ve önlemler)

  • TranilsiprominMAO inhibitörüMajör

    …Syndrome (SS) c ] Agents with blood pressure-reducing effects Use with caution d Hypotension e Non-selective H1 receptor antagonists Contraindicated a Increased anticholinergic effects Beta-adrenergic blockers (see also agents or procedures with blood pressure-reducing effects) Use with the caution d More pronounced bradycardia, postural hypotension e Blood glucose-lowering… (Tranilsipromin etiketi, İlaç etkileşimleri)

Orta düzey etkileşimler (253)

  • AdrenalinsempatomimetikOrta

    Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reactions. (Bisoprolol etiketi, İlaç etkileşimleri)

  • AkarbozantidiyabetikOrta

    However, patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned about these possibilities and bisoprolol fumarate should be used with caution. (Bisoprolol etiketi, Uyarılar)

  • Alfuzosinalfa blokerOrta

    Postural hypotension/syncope: Care should be taken in patients with symptomatic hypotension or who have had a hypotensive response to other medications or are concomitantly treated with antihypertensive medication or nitrates ( 5.1 ) (Alfuzosin etiketi, Uyarılar ve önlemler)

  • AliskirenantihipertansifOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • AlogliptinDPP-4 inhibitörüOrta

    However, patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned about these possibilities and bisoprolol fumarate should be used with caution. (Bisoprolol etiketi, Uyarılar)

  • Alogliptin ve metforminDPP-4 inhibitörüOrta

    However, patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned about these possibilities and bisoprolol fumarate should be used with caution. (Bisoprolol etiketi, Uyarılar)

  • Amiloridpotasyum tutucu diüretikOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • AmiodaronantiaritmikOrta

    Negative Chronotropes digoxin, beta blockers, verapamil, diltiazem, clonidine, ivabradine Potentiates the electrophysiologic and hemodynamic effects of amiodarone, resulting in bradycardia, sinus arrest and AV block. (Amiodaron etiketi, İlaç etkileşimleri)

  • Amlodipindihidropiridin kalsiyum kanal blokeriOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Amlodipin ve atorvastatindihidropiridin kalsiyum kanal blokeriOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Amlodipin ve benazeprildihidropiridin kalsiyum kanal blokeriOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Amlodipin ve olmesartandihidropiridin kalsiyum kanal blokeriOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Amlodipin ve valsartandihidropiridin kalsiyum kanal blokeriOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Arformoterolbeta adrenerjik agonistOrta

    Beta-blockers may decrease effectiveness. (Arformoterol etiketi, İlaç etkileşimleri)

  • AripiprazolantipsikotikOrta

    Antihypertensive Drugs Due to its alpha-adrenergic antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents. (Aripiprazol etiketi, İlaç etkileşimleri)

  • ArmodafinilMSS uyarıcısıOrta

    There was also a slightly greater proportion of patients on NUVIGIL requiring new or increased use of antihypertensive medications (2.9%) compared to patients on placebo (1.8%). (Armodafinil etiketi, Uyarılar ve önlemler)

  • Artikain ve adrenalinlokal anestezikOrta

    Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reactions. (Bisoprolol etiketi, İlaç etkileşimleri)

  • Asebutololbeta blokerOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • AsenapinantipsikotikOrta

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medications, patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), and patients… (Asenapin etiketi, Uyarılar ve önlemler)

  • Aspirin ve dipiridamolantitrombosit ilaçOrta

    Beta Blockers The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow and salt and fluid retention. (Aspirin ve dipiridamol etiketi, İlaç etkileşimleri)

  • Atenololbeta blokerOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Atomoksetinnoradrenalin geri alım inhibitörüOrta

    Antihypertensive Drugs Prevention or Management Increase the frequency of monitoring blood pressure and adjust atomoxetine oral solution dosage as clinically appropriate. (Atomoksetin etiketi, İlaç etkileşimleri)

  • AvanafilPDE5 inhibitörüOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Azilsartananjiyotensin II reseptör blokeri (ARB)Orta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • BeksagliflozinSGLT2 inhibitörüOrta

    However, patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned about these possibilities and bisoprolol fumarate should be used with caution. (Bisoprolol etiketi, Uyarılar)

  • BenazeprilACE inhibitörüOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • BenzfetaminMSS uyarıcısıOrta

    Amphetamines may decrease the hypotensive effect of antihypertensives. (Benzfetamin etiketi, İlaç etkileşimleri)

  • Betaksololbeta blokerOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • BrekspiprazolantipsikotikOrta

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (Brekspiprazol etiketi, Uyarılar ve önlemler)

  • Brimonidinalfa adrenerjik agonistOrta

    Antihypertensives/Cardiac Glycosides Because brimonidine tartrate ophthalmic solution 0.1% and 0.15% may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate ophthalmic solution 0.1% and 0.15% is advised. (Brimonidin etiketi, İlaç etkileşimleri)

  • Brimonidin ve timololalfa adrenerjik agonistOrta

    Antihypertensives/Cardiac Glycosides Because brimonidine tartrate/timolol maleate ophthalmic solution may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate/timolol maleate ophthalmic solution is advised. (Brimonidin ve timolol etiketi, İlaç etkileşimleri)

  • Central Nervous System (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc.). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs. (Bromfeniramin, psödoefedrin ve dekstrometorfan etiketi, İlaç etkileşimleri)

  • Bromokriptindopamin agonistiOrta

    Use caution in patients taking antihypertensive medications. (Bromokriptin etiketi, Uyarılar ve önlemler)

  • Budesonid ve formoterolkortikosteroidOrta

    Beta-blockers: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

  • Bumetanidkıvrım (loop) diüretiğiOrta

    Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

  • Bupivakainlokal anestezikOrta

    Risk of Hypertension and Bradycardia Due to Drug Interactions Between MARCAINE WITH EPINEPHRINE and Nonselective Beta-Adrenergic Antagonists Administration of MARCAINE WITH EPINEPHRINE (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia. (Bupivakain etiketi, Uyarılar ve önlemler)

  • Bupivakain ve adrenalinlokal anestezikOrta

    Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reactions. (Bisoprolol etiketi, İlaç etkileşimleri)

  • BupropionantidepresanOrta

    Drugs Metabolized by CYP2D6: Bupropion inhibits CYP2D6 and can increase concentrations of: antidepressants (e.g., venlafaxine, nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide). (Bupropion etiketi, İlaç etkileşimleri)

  • Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention. (Butalbital, aspirin, kafein ve kodein etiketi, İlaç etkileşimleri)

  • DapagliflozinSGLT2 inhibitörüOrta

    However, patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned about these possibilities and bisoprolol fumarate should be used with caution. (Bisoprolol etiketi, Uyarılar)

  • Dapagliflozin ve metforminSGLT2 inhibitörüOrta

    However, patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned about these possibilities and bisoprolol fumarate should be used with caution. (Bisoprolol etiketi, Uyarılar)

  • DarunavirantiretroviralOrta

    …initial dosing and titration of quetiapine. e.g. perphenazine, risperidone, thioridazine ↑ antipsychotics A decrease in the dose of antipsychotics that are metabolized by CYP3A or CYP2D6 may be needed when co-administered with PREZISTA/ritonavir. β-Blockers : e.g. carvedilol, metoprolol, timolol ↑ beta-blockers Clinical monitoring of patients is recommended. (Darunavir etiketi, İlaç etkileşimleri)

  • Darunavir ve kobisistatantiretroviralOrta

    Initiation of quetiapine in patients taking PREZCOBIX or PREZCOBIX PED : Refer to the quetiapine prescribing information for initial dosing and titration of quetiapine. β-Blockers: e.g. carvedilol, metoprolol, timolol ↑ beta-blockers Clinical monitoring is recommended for co-administration with beta-blockers that are metabolized by CYP2D6. (Darunavir ve kobisistat etiketi, İlaç etkileşimleri)

  • DeksmetilfenidatMSS uyarıcısıOrta

    • Antihypertensive Drugs: Monitor blood pressure. (Deksmetilfenidat etiketi, İlaç etkileşimleri)

  • DietilpropionMSS uyarıcısıOrta

    The pressor effects of diethylpropion and those of other drugs may be additive when the drugs are used concomitantly; conversely, diethylpropion may interfere with antihypertensive drugs (i.e., guanethidine, a-methyldopa). (Dietilpropion etiketi, İlaç etkileşimleri)

  • Digoksindijital glikozidiOrta

    Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart rate. (Bisoprolol etiketi, İlaç etkileşimleri)

  • Dihidroergotaminergot alkaloidiOrta

    Beta Blockers Although the results of a clinical study did not indicate a safety problem associated with the administration of Dihydroergotamine Mesylate Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine. (Dihidroergotamin etiketi, İlaç etkileşimleri)

  • DiklofenakNSAİİOrta

    Intervention: During concomitant use of ZIPSOR and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Diklofenak etiketi, İlaç etkileşimleri)

  • • During concomitant use of diclofenac sodium/misoprostol and ACE inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Diklofenak ve misoprostol etiketi, İlaç etkileşimleri)

  • Diltiazemkalsiyum kanal blokeriOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • DofetilidantiaritmikOrta

    Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas, loop diuretics, potassium sparing diuretics, thiazide diuretics, substrates and inhibitors of tubular… (Dofetilid etiketi, İlaç etkileşimleri)

  • Doksazosinalfa blokerOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • DötetrabenazinVMAT2 inhibitörüOrta

    Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of BISOPROLOL FUMARATE may produce excessive reduction of sympathetic activity. (Bisoprolol etiketi, İlaç etkileşimleri)

  • DronedaronantiaritmikOrta

    Give a low dose of beta-blockers initially, and increase only after ECG verification of good tolerability [see Drug Interactions (7.3) , Clinical Pharmacology (12.3) ] . (Dronedaron etiketi, İlaç etkileşimleri)

  • DulaglutidGLP-1 reseptör agonistiOrta

    However, patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned about these possibilities and bisoprolol fumarate should be used with caution. (Bisoprolol etiketi, Uyarılar)

  • DuloksetinSNRIOrta

    The risk of BP decreases may be greater in patients taking concomitant medications that induce orthostatic hypotension (such as antihypertensives) or are potent CYP1A2 inhibitors [see Drug Interactions ( 7.1 )] and in patients taking duloxetine delayed-release capsules at doses above 60 mg daily. (Duloksetin etiketi, Uyarılar ve önlemler)

  • EksenatidGLP-1 reseptör agonistiOrta

    However, patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned about these possibilities and bisoprolol fumarate should be used with caution. (Bisoprolol etiketi, Uyarılar)

  • Beta-Blockers: e.g., metoprolol timolol ↑ beta-blockers Clinical monitoring is recommended and a dosage decrease of the beta blocker may be necessary when these agents are coadministered with GENVOYA. (Elvitegravir, kobisistat, emtrisitabin ve tenofovir etiketi, İlaç etkileşimleri)

  • EmpagliflozinSGLT2 inhibitörüOrta

    However, patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned about these possibilities and bisoprolol fumarate should be used with caution. (Bisoprolol etiketi, Uyarılar)

  • Empagliflozin ve metforminSGLT2 inhibitörüOrta

    However, patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned about these possibilities and bisoprolol fumarate should be used with caution. (Bisoprolol etiketi, Uyarılar)

  • EnalaprilACE inhibitörüOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Enalapril ve hidroklorotiyazidACE inhibitörüOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • EnalaprilatACE inhibitörüOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Eplerenonaldosteron antagonistiOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Epoetin alfa etiketi, Uyarılar ve önlemler)

  • Epoprostenolprostaglandin analoğuOrta

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Epoprostenol etiketi, İlaç etkileşimleri)

  • Ergotamin ve kafeinergot alkaloidiOrta

    The beta-blocker Inderal (propranolol) has been reported to potentiate the vasoconstrictive action of ergotamine tartrate and caffeine tablets by blocking the vasodilating property of epinephrine. (Ergotamin ve kafein etiketi, İlaç etkileşimleri)

  • Esmololbeta blokerOrta

    Antihypertensive agents clonidine, guanfacine, or moxonidine: Beta blockers also increase the risk of clonidine-, guanfacine-, or moxonidine-withdrawal rebound hypertension. (Esmolol etiketi, İlaç etkileşimleri)

  • Etakrinik asitkıvrım (loop) diüretiğiOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Felodipindihidropiridin kalsiyum kanal blokeriOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • FenelzinMAO inhibitörüOrta

    …hydrochloride desipramine hydrochloride imipramine hydrochloride doxepin carbamazepine cyclobenzaprine HCl amoxapine maprotiline HCl trimipramine maleate protriptyline HCl mirtazapine Phenelzine sulfate should be used with caution in combination with antihypertensive drugs, including thiazide diuretics and β-blockers, since exaggerated hypotensive effects may result. (Fenelzin etiketi, Uyarılar)

  • Fenoksibenzaminalfa blokerOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • FenoprofenNSAİİOrta

    Intervention: During concomitant use of FENOPROFEN CALCIUM with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [ see Warnings and Precautions ( 5.6 ) ]. (Fenoprofen etiketi, İlaç etkileşimleri)

  • FlurbiprofenNSAİİOrta

    Intervention: During concomitant use of flurbiprofen and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Flurbiprofen etiketi, İlaç etkileşimleri)

  • FluvoksaminSSRIOrta

    Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations. (Fluvoksamin etiketi, İlaç etkileşimleri)

  • Formoterolbeta adrenerjik agonistOrta

    • Beta-blockers may decrease effectiveness. (Formoterol etiketi, İlaç etkileşimleri)

  • FosinoprilACE inhibitörüOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Furosemidkıvrım (loop) diüretiğiOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • GlibenklamidsülfonilüreOrta

    However, patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned about these possibilities and bisoprolol fumarate should be used with caution. (Bisoprolol etiketi, Uyarılar)

  • Glibenklamid ve metforminsülfonilüreOrta

    However, patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned about these possibilities and bisoprolol fumarate should be used with caution. (Bisoprolol etiketi, Uyarılar)

  • GlimepiridsülfonilüreOrta

    However, patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned about these possibilities and bisoprolol fumarate should be used with caution. (Bisoprolol etiketi, Uyarılar)

  • GlipizidsülfonilüreOrta

    However, patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned about these possibilities and bisoprolol fumarate should be used with caution. (Bisoprolol etiketi, Uyarılar)

  • Glipizid ve metforminsülfonilüreOrta

    However, patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned about these possibilities and bisoprolol fumarate should be used with caution. (Bisoprolol etiketi, Uyarılar)

  • Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Glukagon etiketi, İlaç etkileşimleri)

  • Guanfasinalfa adrenerjik agonistOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • HidralazinvazodilatörOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Hidroklorotiyazidtiyazid diüretikOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • During concomitant use of hydrocodone bitartrate and ibuprofen tablets and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Hidrokodon ve ibuprofen etiketi, İlaç etkileşimleri)

  • İbuprofenNSAİİOrta

    Intervention: During concomitant use of CALDOLOR and ACE-inhibitors, ARBs, or beta- blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (İbuprofen etiketi, İlaç etkileşimleri)

  • Intervention: During concomitant use of ibuprofen and famotidine tablet and ACE-inhibitors, ARBs, or beta- blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (İbuprofen ve famotidin etiketi, İlaç etkileşimleri)

  • İloperidonantipsikotikOrta

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (İloperidon etiketi, Uyarılar ve önlemler)

  • İndapamidtiyazid diüretikOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • İndometazinNSAİİOrta

    Intervention: During concomitant use of INDOCIN and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (İndometazin etiketi, İlaç etkileşimleri)

  • İnsülin aspartinsülinOrta

    Nonselective beta-blockers may potentiate insulin-induced hypoglycemia and delay recovery of serum glucose levels. (Bisoprolol etiketi, Uyarılar)

  • İnsülin degludekinsülinOrta

    Nonselective beta-blockers may potentiate insulin-induced hypoglycemia and delay recovery of serum glucose levels. (Bisoprolol etiketi, Uyarılar)

  • İnsülin detemirinsülinOrta

    Nonselective beta-blockers may potentiate insulin-induced hypoglycemia and delay recovery of serum glucose levels. (Bisoprolol etiketi, Uyarılar)

  • İnsülin glarjininsülinOrta

    Nonselective beta-blockers may potentiate insulin-induced hypoglycemia and delay recovery of serum glucose levels. (Bisoprolol etiketi, Uyarılar)

  • İnsülin lisproinsülinOrta

    Nonselective beta-blockers may potentiate insulin-induced hypoglycemia and delay recovery of serum glucose levels. (Bisoprolol etiketi, Uyarılar)

  • İrbesartananjiyotensin II reseptör blokeri (ARB)Orta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • İrbesartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Orta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • İsradipindihidropiridin kalsiyum kanal blokeriOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • İtrakonazolazol antifungalOrta

    Beta Blockers Nadolol Monitor for adverse reactions. (İtrakonazol etiketi, İlaç etkileşimleri)

  • The risk of bradycardia increases with concomitant administration of drugs that slow heart rate (e.g., digoxin, amiodarone, beta-blockers). (İvabradin etiketi, İlaç etkileşimleri)

  • İzoflurangenel anestezikOrta

    Concomitant Use with Beta Blockers Concomitant use of beta blockers may exaggerate the cardiovascular effects of inhalational anesthetics, including hypotension and negative inotropic effects. (İzofluran etiketi, İlaç etkileşimleri)

  • Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • KanagliflozinSGLT2 inhibitörüOrta

    However, patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned about these possibilities and bisoprolol fumarate should be used with caution. (Bisoprolol etiketi, Uyarılar)

  • Kandesartananjiyotensin II reseptör blokeri (ARB)Orta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Kandesartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Orta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • KaptoprilACE inhibitörüOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Symptomatic postural hypotension has occurred when carbidopa, given with levodopa or carbidopa-levodopa combination products, was added to the treatment of a patient receiving antihypertensive drugs. (Karbidopa etiketi, İlaç etkileşimleri)

  • Karbidopa ve levodopadopaminerjik ilaçOrta

    Antihypertensive drugs: May cause symptomatic postural hypotension. (Karbidopa ve levodopa etiketi, İlaç etkileşimleri)

  • Karbidopa, levodopa ve entakapondopaminerjik ilaçOrta

    Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (Karbidopa, levodopa ve entakapon etiketi, İlaç etkileşimleri)

  • KariprazinantipsikotikOrta

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (Kariprazin etiketi, Uyarılar ve önlemler)

  • Karvedilolbeta blokerOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • KetiapinantipsikotikOrta

    Quetiapine should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (Ketiapin etiketi, Uyarılar ve önlemler)

  • Ketokonazolazol antifungalOrta

    Antivirals indinavir, maraviroc, saquinavir Beta Blockers nadolol Calcium Channel Blockers felodipine, nisoldipine other dihydropyridines, verapamil Calcium channel blockers can have a negative inotropic effect which may be additive to those of ketoconazole. (Ketokonazol etiketi, İlaç etkileşimleri)

  • KinaprilACE inhibitörüOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Kinapril ve hidroklorotiyazidACE inhibitörüOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Klonidinalfa adrenerjik agonistOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Klorotiyazidtiyazid diüretikOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Klortalidontiyazid diüretikOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Labetalolbeta blokerOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • LakozamidantikonvülsanOrta

    VIMPAT should also be used with caution in patients on concomitant medications that affect cardiac conduction, including sodium channel blockers, beta-blockers, calcium channel blockers, potassium channel blockers, and medications that prolong the PR interval [see Drug Interactions (7.2) ] . (Lakozamid etiketi, Uyarılar ve önlemler)

  • Bradycardia-Inducing Drugs (e.g., beta-blockers) : Lanreotide Injection may decrease heart rate. (Lanreotid etiketi, İlaç etkileşimleri)

  • Patients also taking beta blockers, or those with underlying cardiac comorbidities and/or advanced liver disease, may be at increased risk for symptomatic bradycardia with coadministration of amiodarone. (Ledipasvir ve sofosbuvir etiketi, Uyarılar ve önlemler)

  • Levosalbutamolbeta adrenerjik agonistOrta

    In this setting, cardioselective beta-blockers should be considered, although they should be administered with caution. (Levosalbutamol etiketi, İlaç etkileşimleri)

  • Levotiroksintiroid hormonuOrta

    Drug or Drug Class Effect Beta-adrenergic antagonists e.g., Propranolol > 160 mg/day) In patients treated with large doses of propranolol (> 160 mg/day), T 3 and T 4 levels change slightly, TSH levels remain normal, and patients are clinically euthyroid. (Levotiroksin etiketi, İlaç etkileşimleri)

  • Lidokain ve adrenalinlokal anestezikOrta

    Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reactions. (Bisoprolol etiketi, İlaç etkileşimleri)

  • LinagliptinDPP-4 inhibitörüOrta

    However, patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned about these possibilities and bisoprolol fumarate should be used with caution. (Bisoprolol etiketi, Uyarılar)

  • Linagliptin ve metforminDPP-4 inhibitörüOrta

    However, patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned about these possibilities and bisoprolol fumarate should be used with caution. (Bisoprolol etiketi, Uyarılar)

  • LiraglutidGLP-1 reseptör agonistiOrta

    However, patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned about these possibilities and bisoprolol fumarate should be used with caution. (Bisoprolol etiketi, Uyarılar)

  • LisinoprilACE inhibitörüOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Liyotironintiroid hormonuOrta

    Drug or Drug Class Effect Beta-adrenergic antagonists (e.g., Propranolol >160 mg/day) In patients treated with large doses of propranolol (>160 mg/day), T3 and T4 levels change, TSH levels remain normal, and patients are clinically euthyroid. (Liyotironin etiketi, İlaç etkileşimleri)

  • Lofeksidinalfa adrenerjik agonistOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Lopinavir ve ritonavirantiretroviralOrta

    The impact on the PR interval of co-administration of KALETRA with other drugs that prolong the PR interval (including calcium channel blockers, beta-adrenergic blockers, digoxin and atazanavir) has not been evaluated. (Lopinavir ve ritonavir etiketi, Uyarılar ve önlemler)

  • Losartananjiyotensin II reseptör blokeri (ARB)Orta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Losartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Orta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • LumateperonantipsikotikOrta

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (Lumateperon etiketi, Uyarılar ve önlemler)

  • LurasidonantipsikotikOrta

    Patients at increased risk of these adverse reactions or at increased risk of developing complications from hypotension include those with dehydration, hypovolemia, treatment with antihypertensive medication, history of cardiovascular disease (e.g., heart failure, myocardial infarction, ischemia, or conduction abnormalities), history of cerebrovascular disease,… (Lurasidon etiketi, Uyarılar ve önlemler)

  • Mefenamik asitNSAİİOrta

    Intervention: During concomitant use of mefenamic acid and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Mefenamik asit etiketi, İlaç etkileşimleri)

  • MeflokinantimalaryalOrta

    There is one report of cardiopulmonary arrest, with full recovery, in a patient who was taking a beta blocker (propranolol) (see PRECAUTIONS, Cardiac Effects ). (Meflokin etiketi, İlaç etkileşimleri)

  • MekamilaminantihipertansifOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • MeloksikamNSAİİOrta

    Intervention: During concomitant use of QAMZOVA and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Meloksikam etiketi, İlaç etkileşimleri)

  • MetforminbiguanidOrta

    However, patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned about these possibilities and bisoprolol fumarate should be used with caution. (Bisoprolol etiketi, Uyarılar)

  • MetildopaantihipertansifOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Metilergometrinergot alkaloidiOrta

    Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (Metilergometrin etiketi, İlaç etkileşimleri)

  • MetilfenidatMSS uyarıcısıOrta

    Antihypertensive Drugs: Monitor blood pressure. (Metilfenidat etiketi, İlaç etkileşimleri)

  • Metimazolantitiroid ilaçOrta

    …(oral): Due to potential inhibition of vitamin K activity by methimazole, the activity of oral anticoagulants (e.g., warfarin) may be increased; additional monitoring of PT/INR should be considered, especially before surgical procedures. β-adrenergic blocking agents: Hyperthyroidism may cause an increased clearance of beta blockers with a high extraction ratio. (Metimazol etiketi, İlaç etkileşimleri)

  • Metoprololbeta blokerOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • MiglitolantidiyabetikOrta

    However, patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned about these possibilities and bisoprolol fumarate should be used with caution. (Bisoprolol etiketi, Uyarılar)

  • MirtazapinantidepresanOrta

    REMERON/REMERONSolTab should be used with caution in patients with known cardiovascular or cerebrovascular disease that could be exacerbated by hypotension (history of myocardial infarction, angina, or ischemic stroke) and conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medication). (Mirtazapin etiketi, Uyarılar ve önlemler)

  • ModafinilMSS uyarıcısıOrta

    However, a retrospective analysis of the use of antihypertensive medication in these studies showed that a greater proportion of patients on PROVIGIL required new or increased use of antihypertensive medications (2.4%) compared to patients on placebo (0.7%). (Modafinil etiketi, Uyarılar ve önlemler)

  • MoeksiprilACE inhibitörüOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Patients receiving concomitant negative chronotropic drugs (e.g., beta blockers) may be more at risk for hypotension in case of hypersensitivity reaction. (Motiksafortid etiketi, Uyarılar ve önlemler)

  • Nadololbeta blokerOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Naltrekson ve bupropionopioid antagonistiOrta

    Drugs Metabolized by CYP2D6: Bupropion inhibits CYP2D6 and can increase concentrations of antidepressants, (e.g., selective serotonin reuptake inhibitors and many tricyclics), antipsychotics (e.g., haloperidol, risperidone and thioridazine), beta-blockers (e.g., metoprolol) and Type 1C antiarrhythmics (e.g., propafenone and flecainide). (Naltrekson ve bupropion etiketi, İlaç etkileşimleri)

  • NaproksenNSAİİOrta

    ( 5.3 Hepatotoxicity) Hypertension: Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Naproksen etiketi, Uyarılar ve önlemler)

  • Intervention : • During concomitant use of naproxen and esomeprazole magnesium delayed-release tablets and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Naproksen ve esomeprazol etiketi, İlaç etkileşimleri)

  • NateglinidmeglitinidOrta

    However, patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned about these possibilities and bisoprolol fumarate should be used with caution. (Bisoprolol etiketi, Uyarılar)

  • NiasinOrta

    Antihypertensive Therapy Niacin may potentiate the effects of ganglionic blocking agents and vasoactive drugs resulting in postural hypotension. (Niasin etiketi, İlaç etkileşimleri)

  • Nifedipindihidropiridin kalsiyum kanal blokeriOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Nikardipindihidropiridin kalsiyum kanal blokeriOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Nimodipindihidropiridin kalsiyum kanal blokeriOrta

    Blood Pressure Lowering Drugs Nimodipine may increase the blood pressure lowering effect of concomitantly administered anti-hypertensives such as diuretics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, other calcium channel blockers, α-adrenergic blockers, PDE5 inhibitors, and α-methyldopa. (Nimodipin etiketi, İlaç etkileşimleri)

  • Nisoldipindihidropiridin kalsiyum kanal blokeriOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • NitrogliserinnitratOrta

    Antihypertensives: Possible additive hypotensive effects. (Nitrogliserin etiketi, İlaç etkileşimleri)

  • NitroprussidvazodilatörOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • OksaprozinNSAİİOrta

    Intervention: During concomitant use of OXAPROZIN CAPSULES and ACE inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Oksaprozin etiketi, İlaç etkileşimleri)

  • OksimetazolindekonjestanOrta

    Caution in using drugs such as beta-blockers, anti-hypertensives, and/or cardiac glycosides is advised. (Oksimetazolin etiketi, İlaç etkileşimleri)

  • Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (Oktreotid etiketi, Uyarılar ve önlemler)

  • OlanzapinantipsikotikOrta

    …of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, and conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications) where the occurrence of syncope, or hypotension and/or bradycardia might put the patient at increased medical risk. (Olanzapin etiketi, Uyarılar ve önlemler)

  • Olanzapin ve fluoksetinantipsikotikOrta

    …and fluoxetine capsules should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (Olanzapin ve fluoksetin etiketi, Uyarılar ve önlemler)

  • Olmesartananjiyotensin II reseptör blokeri (ARB)Orta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Olmesartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Orta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Olmesartan, amlodipin ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Orta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • PaliperidonantipsikotikOrta

    Use ERZOFRI with caution in patients with known cardiovascular disease (e.g., heart failure, history of myocardial infarction or ischemia, conduction abnormalities), cerebrovascular disease, or conditions that predispose the patient to hypotension (e.g., dehydration, hypovolemia, and treatment with antihypertensive medications). (Paliperidon etiketi, Uyarılar ve önlemler)

  • • Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Parasetamol ve ibuprofen etiketi, Uyarılar ve önlemler)

  • Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (Pasireotid etiketi, Uyarılar ve önlemler)

  • Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib etiketi, Uyarılar ve önlemler)

  • PentoksifilinmetilksantinOrta

    Small decreases in blood pressure have been observed in some patients treated with pentoxifylline extended-release tablets; periodic systemic blood pressure monitoring is recommended for patients receiving concomitant antihypertensive therapy. (Pentoksifilin etiketi, İlaç etkileşimleri)

  • PerindoprilACE inhibitörüOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Pilokarpinkolinerjik agonistOrta

    Drug Interactions Pilocarpine should be administered with caution to patients taking beta-adrenergic antagonists because of the possibility of conduction disturbances. (Pilokarpin etiketi, İlaç etkileşimleri)

  • Pindololbeta blokerOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • PioglitazontiyazolidindionOrta

    However, patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned about these possibilities and bisoprolol fumarate should be used with caution. (Bisoprolol etiketi, Uyarılar)

  • Pioglitazon ve glimepiridtiyazolidindionOrta

    However, patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned about these possibilities and bisoprolol fumarate should be used with caution. (Bisoprolol etiketi, Uyarılar)

  • Pioglitazon ve metformintiyazolidindionOrta

    However, patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned about these possibilities and bisoprolol fumarate should be used with caution. (Bisoprolol etiketi, Uyarılar)

  • Piridostigminkolinesteraz inhibitörüOrta

    Use with caution in persons with increased risk of anticholinergic reactions, such as persons with bronchial asthma, chronic obstructive pulmonary disease, bradycardia, cardiac arrhythmias, beta blocker treatment (increased risk of anticholinergic reactions). (Piridostigmin etiketi, Uyarılar ve önlemler)

  • PiroksikamNSAİİOrta

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (Piroksikam etiketi, İlaç etkileşimleri)

  • PonesimodimmünosüpresanOrta

    Experience with PONVORY is limited in patients receiving concurrent therapy with drugs that decrease heart rate (e.g., beta-blockers, non-dihydropyridine calcium channel blockers - diltiazem and verapamil, and other drugs that may decrease heart rate such as digoxin). (Ponesimod etiketi, Uyarılar ve önlemler)

  • Prazosinalfa blokerOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Prilokain ve adrenalinlokal anestezikOrta

    Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reactions. (Bisoprolol etiketi, İlaç etkileşimleri)

  • PropafenonantiaritmikOrta

    In clinical trials using propafenone immediate-release tablets, patients who were receiving beta-blockers concurrently did not experience an increased incidence of side effects. (Propafenon etiketi, İlaç etkileşimleri)

  • Propiltiourasilantitiroid ilaçOrta

    Beta-adrenergic blocking agents: Hyperthyroidism may cause an increased clearance of beta blockers with a high extraction ratio. (Propiltiourasil etiketi, İlaç etkileşimleri)

  • Propranololbeta blokerOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • RamiprilACE inhibitörüOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Nonselective beta-blockers may potentiate insulin-induced hypoglycemia and delay recovery of serum glucose levels. (Bisoprolol etiketi, Uyarılar)

  • RifampisinantibiyotikOrta

    Concurrent use of rifampin increases the metabolic clearance of BISOPROLOL FUMARATE, resulting in a shortened elimination half-life of BISOPROLOL FUMARATE. (Bisoprolol etiketi, İlaç etkileşimleri)

  • RifapentinantibiyotikOrta

    …Anticonvulsants Phenytoin Antimalarials Quinine Azole Antifungals Fluconazole, itraconazole, ketoconazole Antipsychotics Haloperidol Barbiturates Phenobarbital Benzodiazepines Diazepam Beta-Blockers Propranolol Calcium Channel Blockers Diltiazem, nifedipine, verapamil Cardiac Glycoside Preparations Digoxin Corticosteroids Prednisone Fibrates Clofibrate Oral Hypoglycemics… (Rifapentin etiketi, İlaç etkileşimleri)

  • RiosiguatvazodilatörOrta

    Consider the potential for symptomatic hypotension or ischemia in patients with hypovolemia, severe left ventricular outflow obstruction, resting hypotension, autonomic dysfunction, or concomitant treatment with antihypertensives or strong CYP and P-gp/BCRP inhibitors [see Drug Interactions (7.2) and Clinical Pharmacology (12.3) ] . (Riosiguat etiketi, Uyarılar ve önlemler)

  • RisperidonantipsikotikOrta

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (Risperidon etiketi, Uyarılar ve önlemler)

  • RitonavirantiretroviralOrta

    The impact on the PR interval of co-administration of ritonavir with other drugs that prolong the PR interval (including calcium channel blockers, beta-adrenergic blockers, digoxin and atazanavir) has not been evaluated. (Ritonavir etiketi, Uyarılar ve önlemler)

  • Ropivakainlokal anestezikOrta

    Patients on beta-blockers may not manifest changes in heart rate, but blood pressure monitoring can detect a rise in systolic blood pressure. (Ropivakain etiketi, Uyarılar ve önlemler)

  • SaksagliptinDPP-4 inhibitörüOrta

    However, patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned about these possibilities and bisoprolol fumarate should be used with caution. (Bisoprolol etiketi, Uyarılar)

  • Saksagliptin ve metforminDPP-4 inhibitörüOrta

    However, patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned about these possibilities and bisoprolol fumarate should be used with caution. (Bisoprolol etiketi, Uyarılar)

  • Sakubitril ve valsartananjiyotensin II reseptör blokeri (ARB)Orta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Salbutamolbeta adrenerjik agonistOrta

    Beta-blockers: Use with caution. (Salbutamol etiketi, İlaç etkileşimleri)

  • Salmeterolbeta adrenerjik agonistOrta

    • Beta-blockers: Use with caution. (Salmeterol etiketi, İlaç etkileşimleri)

  • SelekoksibNSAİİOrta

    Intervention: • During concomitant use of VYSCOXA and ACE inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Selekoksib etiketi, İlaç etkileşimleri)

  • SemaglutidGLP-1 reseptör agonistiOrta

    However, patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned about these possibilities and bisoprolol fumarate should be used with caution. (Bisoprolol etiketi, Uyarılar)

  • Sevimelinkolinerjik agonistOrta

    DRUG INTERACTIONS Cevimeline should be administered with caution to patients taking beta adrenergic antagonists, because of the possibility of conduction disturbances. (Sevimelin etiketi, İlaç etkileşimleri)

  • Siklobenzaprinkas gevşeticiOrta

    …concomitant use of TONMYA with: MAO inhibitors may be life-threatening [see Contraindications (4) ] , Alcohol, barbiturates, and other CNS depressants may increase the risk of adverse reactions associated with these drugs, Tramadol may increase the seizure risk, Guanethidine or other similar acting drugs may block the antihypertensive action of these drugs. (Siklobenzaprin etiketi, İlaç etkileşimleri)

  • SiklosporinimmünosüpresanOrta

    If hypertension persists, the dose of Neoral should be further reduced or blood pressure should be controlled with antihypertensive agents. (Siklosporin etiketi, Önlemler)

  • SildenafilPDE5 inhibitörüOrta

    Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (Sildenafil etiketi, Uyarılar ve önlemler)

  • Silodosinalfa blokerOrta

    However, patients in the Phase 3 clinical studies taking concomitant antihypertensive medications with silodosin capsules did not experience a significant increase in the incidence of syncope, dizziness, or orthostasis. (Silodosin etiketi, Uyarılar ve önlemler)

  • SitagliptinDPP-4 inhibitörüOrta

    However, patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned about these possibilities and bisoprolol fumarate should be used with caution. (Bisoprolol etiketi, Uyarılar)

  • Sitagliptin ve metforminDPP-4 inhibitörüOrta

    However, patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned about these possibilities and bisoprolol fumarate should be used with caution. (Bisoprolol etiketi, Uyarılar)

  • Patients also taking beta blockers, or those with underlying cardiac comorbidities and/or advanced liver disease may be at increased risk for symptomatic bradycardia with coadministration of amiodarone. (Sofosbuvir ve velpatasvir etiketi, Uyarılar ve önlemler)

  • Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Spironolaktonaldosteron antagonistiOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Spironolakton ve hidroklorotiyazidaldosteron antagonistiOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Monitor patients to assure diuretic efficacy including antihypertensive effects. (Sumatriptan ve naproksen etiketi, İlaç etkileşimleri)

  • Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib etiketi, Uyarılar ve önlemler)

  • TakrolimusimmünosüpresanOrta

    • Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (Takrolimus etiketi, Uyarılar ve önlemler)

  • Telmisartananjiyotensin II reseptör blokeri (ARB)Orta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Telmisartan ve amlodipinanjiyotensin II reseptör blokeri (ARB)Orta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Telmisartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Orta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Terazosinalfa blokerOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Terbutalinbeta adrenerjik agonistOrta

    In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution. (Terbutalin etiketi, Önlemler)

  • TestosteronandrojenOrta

    In patients with hypertension on antihypertensive therapy, TLANDO increased the mean systolic/diastolic BP by 4.8/1.6 mm Hg from baseline. [see Adverse Reactions ( 6.1 )] . (Testosteron etiketi, Uyarılar ve önlemler)

  • TetrabenazinVMAT2 inhibitörüOrta

    Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of BISOPROLOL FUMARATE may produce excessive reduction of sympathetic activity. (Bisoprolol etiketi, İlaç etkileşimleri)

  • TirzepatidGLP-1 reseptör agonistiOrta

    Nonselective beta-blockers may potentiate insulin-induced hypoglycemia and delay recovery of serum glucose levels. (Bisoprolol etiketi, Uyarılar)

  • Tizanidinkas gevşeticiOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Torasemidkıvrım (loop) diüretiğiOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • TrandolaprilACE inhibitörüOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • TrazodonantidepresanOrta

    Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (Trazodon etiketi, Uyarılar ve önlemler)

  • Triamterenpotasyum tutucu diüretikOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Triamteren ve hidroklorotiyazidpotasyum tutucu diüretikOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Umeklidinyum ve vilanterolantikolinerjikOrta

    • Beta-blockers: Use with caution. (Umeklidinyum ve vilanterol etiketi, İlaç etkileşimleri)

  • ValbenazinVMAT2 inhibitörüOrta

    Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of BISOPROLOL FUMARATE may produce excessive reduction of sympathetic activity. (Bisoprolol etiketi, İlaç etkileşimleri)

  • Valsartananjiyotensin II reseptör blokeri (ARB)Orta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Valsartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Orta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • VardenafilPDE5 inhibitörüOrta

    Vardenafil hydrochloride tablets can potentiate the hypotensive effects of nitrates, alpha- blockers, and antihypertensives. (Vardenafil etiketi, İlaç etkileşimleri)

  • VarfarinantikoagülanOrta

    There was no effect of BISOPROLOL FUMARATE on prothrombin time in patients on stable doses of warfarin. (Bisoprolol etiketi, İlaç etkileşimleri)

  • VenlafaksinSNRIOrta

    Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Venlafaksin etiketi, İlaç etkileşimleri)

  • Verapamilkalsiyum kanal blokeriOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • ZileutonCYP1A2 inhibitörüOrta

    Zileuton increases propranolol levels and beta-blocker activity. (Zileuton etiketi, İlaç etkileşimleri)

  • ZiprasidonantipsikotikOrta

    Ziprasidone should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (Ziprasidon etiketi, Uyarılar ve önlemler)

Minör değinmeler (50)

  • AdenozinantiaritmikMinör

    BISOPROLOL FUMARATE should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently. (Bisoprolol etiketi, İlaç etkileşimleri)

  • AklidinyumantikolinerjikMinör

    A beta 2 agonist (bronchodilator) should be made available. (Bisoprolol etiketi, Uyarılar)

  • AminofilinmetilksantinMinör

    A beta 2 agonist (bronchodilator) should be made available. (Bisoprolol etiketi, Uyarılar)

  • ButorfanolopioidMinör

    In such cases, butorphanol should be discontinued and the hypertension treated with antihypertensive drugs. (Butorfanol etiketi, Uyarılar)

  • DekstroamfetaminMSS uyarıcısıMinör

    Antihypertensives Amphetamines may antagonize the hypotensive effects of antihypertensives. (Dekstroamfetamin etiketi, İlaç etkileşimleri)

  • Desipramintrisiklik antidepresanMinör

    This drug is capable of blocking the antihypertensive effect of guanethidine and similarly acting compounds. (Desipramin etiketi, Uyarılar)

  • Desogestrel ve etinilestradioloral kontraseptifMinör

    If other contraceptive methods are not suitable, hormonal contraceptive therapy may continue combined with antihypertensive therapy. (Desogestrel ve etinilestradiol etiketi, Uyarılar)

  • DiflunisalNSAİİMinör

    Drug Interactions ACE-inhibitors and Angiotensin II Anagonists Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors and angiotensin II antagonists. (Diflunisal etiketi, İlaç etkileşimleri)

  • DisopiramidantiaritmikMinör

    BISOPROLOL FUMARATE should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently. (Bisoprolol etiketi, İlaç etkileşimleri)

  • Dorzolamid ve timololkarbonik anhidraz inhibitörüMinör

    Drug Interactions BISOPROLOL FUMARATE should not be combined with other beta-blocking agents. (Bisoprolol etiketi, İlaç etkileşimleri)

  • EfedrinsempatomimetikMinör

    Examples: α-adrenergic antagonists, β-adrenergic receptor antagonists, reserpine, quinidine, mephentermine Other Drug Interactions G u anethidine C linical Impact: Ephedrine may inhibit the neuron blockage produced by guanethidine, resulting in loss of antihypertensive effectiveness. (Efedrin etiketi, İlaç etkileşimleri)

  • EtodolakNSAİİMinör

    Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Etodolak etiketi, İlaç etkileşimleri)

  • Finasterid5-alfa redüktaz inhibitörüMinör

    …PROSCAR was concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, α-blockers, angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), benzodiazepines,… (Finasterid etiketi, İlaç etkileşimleri)

  • FingolimodimmünosüpresanMinör

    Drugs That Slow Heart Rate or Atrioventricular Conduction (e.g., beta blockers or diltiazem) Experience with GILENYA in patients receiving concurrent therapy with drugs that slow the heart rate or AV conduction (e.g., beta blockers, digoxin, or heart rate-slowing calcium channel blockers, such as diltiazem or verapamil) is limited. (Fingolimod etiketi, İlaç etkileşimleri)

  • Flutikazon ve salmeterolkortikosteroidMinör

    A beta 2 agonist (bronchodilator) should be made available. (Bisoprolol etiketi, Uyarılar)

  • İbutilidantiaritmikMinör

    BISOPROLOL FUMARATE should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently. (Bisoprolol etiketi, İlaç etkileşimleri)

  • ACE Inhibitors FIRAZYR is a bradykinin B2 receptor antagonist and thereby has the potential to have a pharmacodynamic interaction with ACE inhibitors where FIRAZYR may attenuate the antihypertensive effect of ACE inhibitors. (İkatibant etiketi, İlaç etkileşimleri)

  • İpratropiumantikolinerjikMinör

    A beta 2 agonist (bronchodilator) should be made available. (Bisoprolol etiketi, Uyarılar)

  • İpratropium ve salbutamolantikolinerjikMinör

    A beta 2 agonist (bronchodilator) should be made available. (Bisoprolol etiketi, Uyarılar)

  • İzoprenalinbeta adrenerjik agonistMinör

    A beta 2 agonist (bronchodilator) should be made available. (Bisoprolol etiketi, Uyarılar)

  • KarbamazepinantikonvülsanMinör

    CNS depressants include: alcohol, opioid analgesics, benzodiazepines, tricyclic antidepressants, sedative/hypnotics, anticonvulsants, antipsychotics, antihistamines, anticholinergics, alpha and beta blockers, general anesthetics, muscle relaxants, and illicit CNS depressants. (Karbamazepin etiketi, İlaç etkileşimleri)

  • KetoprofenNSAİİMinör

    ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Ketoprofen etiketi, Uyarılar ve önlemler)

  • KetorolakNSAİİMinör

    Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors and/or angiotensin II receptor antagonists. (Ketorolak etiketi, İlaç etkileşimleri)

  • KinidinantiaritmikMinör

    BISOPROLOL FUMARATE should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently. (Bisoprolol etiketi, İlaç etkileşimleri)

  • KlorpromazinantipsikotikMinör

    Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

  • Kolestipolsafra asidi bağlayıcıMinör

    Effects on the absorption of other beta-blockers have not been determined. (Kolestipol etiketi, İlaç etkileşimleri)

  • Levotiroksin ve liyotironintiroid hormonuMinör

    Abrupt withdrawal of beta-blockade may be followed by an exacerbation of the symptoms of hyperthyroidism or may precipitate thyroid storm. (Bisoprolol etiketi, Uyarılar)

  • Lidokainlokal anestezikMinör

    BISOPROLOL FUMARATE should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently. (Bisoprolol etiketi, İlaç etkileşimleri)

  • Lidokain ve prilokainlokal anestezikMinör

    BISOPROLOL FUMARATE should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently. (Bisoprolol etiketi, İlaç etkileşimleri)

  • MeksiletinantiaritmikMinör

    BISOPROLOL FUMARATE should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently. (Bisoprolol etiketi, İlaç etkileşimleri)

  • Mirabegronbeta adrenerjik agonistMinör

    A beta 2 agonist (bronchodilator) should be made available. (Bisoprolol etiketi, Uyarılar)

  • NabumetonNSAİİMinör

    Drug Interactions: ACE-inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Nabumeton etiketi, İlaç etkileşimleri)

  • Nortriptilintrisiklik antidepresanMinör

    The antihypertensive action of guanethidine and similar agents may be blocked. (Nortriptilin etiketi, Uyarılar)

  • PerfenazinantipsikotikMinör

    Drug Interactions Metabolism of a number of medications, including antipsychotics, antidepressants, β-blockers, and antiarrhythmics, occurs through the cytochrome P450 2D6 isoenzyme (debrisoquine hydroxylase). (Perfenazin etiketi, İlaç etkileşimleri)

  • ProkainamidantiaritmikMinör

    BISOPROLOL FUMARATE should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently. (Bisoprolol etiketi, İlaç etkileşimleri)

  • ProklorperazinantipsikotikMinör

    Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concomitantly. (Proklorperazin etiketi, Önlemler)

  • Protriptilintrisiklik antidepresanMinör

    Protriptyline may block the antihypertensive effect of guanethidine or similarly acting compounds. (Protriptilin etiketi, Uyarılar)

  • SalsalatNSAİİMinör

    DRUG INTERACTIONS ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Salsalat etiketi, İlaç etkileşimleri)

  • Sotalolbeta blokerMinör

    Drug Interactions BISOPROLOL FUMARATE should not be combined with other beta-blocking agents. (Bisoprolol etiketi, İlaç etkileşimleri)

  • SulindakNSAİİMinör

    Drug Interactions ACE-Inhibitors and Angiotensin II Antagonists Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors and angiotensin II antagonists. (Sulindak etiketi, İlaç etkileşimleri)

  • TeofilinmetilksantinMinör

    A beta 2 agonist (bronchodilator) should be made available. (Bisoprolol etiketi, Uyarılar)

  • TerbinafinantifungalMinör

    Drugs predominantly metabolized by the CYP450 2D6 isozyme include the following drug classes: tricyclic antidepressants, selective serotonin reuptake inhibitors, beta-blockers, antiarrhythmics class 1C (e.g., flecainide and propafenone) and monoamine oxidase inhibitors Type B. (Terbinafin etiketi, İlaç etkileşimleri)

  • Teriparatidtiroid hormonuMinör

    Abrupt withdrawal of beta-blockade may be followed by an exacerbation of the symptoms of hyperthyroidism or may precipitate thyroid storm. (Bisoprolol etiketi, Uyarılar)

  • Timololbeta blokerMinör

    Drug Interactions BISOPROLOL FUMARATE should not be combined with other beta-blocking agents. (Bisoprolol etiketi, İlaç etkileşimleri)

  • TiotropiumantikolinerjikMinör

    A beta 2 agonist (bronchodilator) should be made available. (Bisoprolol etiketi, Uyarılar)

  • TolmetinNSAİİMinör

    DRUG INTERACTIONS ACE Inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE Inhibitors. (Tolmetin etiketi, İlaç etkileşimleri)

  • TolvaptanMinör

    Angiotensin Receptor Blockers, Angiotensin Converting Enzyme Inhibitors and Potassium Sparing Diuretics Although specific interaction studies were not performed, in clinical studies, tolvaptan was used concomitantly with beta-blockers, angiotensin receptor blockers, angiotensin converting enzyme inhibitors and potassium sparing diuretics. (Tolvaptan etiketi, İlaç etkileşimleri)

  • TrifluoperazinantipsikotikMinör

    Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concurrently. (Trifluoperazin etiketi, Önlemler)

  • UmeklidinyumantikolinerjikMinör

    A beta 2 agonist (bronchodilator) should be made available. (Bisoprolol etiketi, Uyarılar)

  • Vibegronbeta adrenerjik agonistMinör

    A beta 2 agonist (bronchodilator) should be made available. (Bisoprolol etiketi, Uyarılar)

Anlamlı etkileşim olmadığı bildirilenler (2)

  • Asetazolamidkarbonik anhidraz inhibitörüEtkileşim yok

    Pharmacokinetic studies document no clinically relevant interactions with other agents given concomitantly, including thiazide diuretics and cimetidine. (Bisoprolol etiketi, İlaç etkileşimleri)

  • SimetidinH2 blokeriEtkileşim yok

    Pharmacokinetic studies document no clinically relevant interactions with other agents given concomitantly, including thiazide diuretics and cimetidine. (Bisoprolol etiketi, İlaç etkileşimleri)

Kullandığınız her şeyi Bisoprolol ile karşılaştırın. Tüm listenizi ekleyin; her çift tek seferde kontrol edilir.

Sorgulama aracında aç

Tıbbi tavsiye değildir. Şiddet derecesi sizin koşullarınızı değil, etiketin ifadesini yansıtır. “Majör” işareti gözetim altında olağan bir uygulama olabilir, “minör” işareti ise yüksek dozlarda önem kazanabilir. Bir eczacıya danışın.